for the Period Ended 31 December 2025
| Directors report | |
| Profit and loss | |
| Balance sheet | |
| Additional notes | |
| Balance sheet notes |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 December 2025
Principal activities of the company
Additional information
Qualifying third party indemnity provisions The Company has made qualifying third party indemnity provisions for the benefit of its directors during the year. These provisions remain in force at the reporting date. Going concern At the time of approving the financial statements, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements. Post balance sheet events Subsequent to the year end, Certara Group entered into a definitive agreement for the sale of Insight Medical Writing Limited to a third party. The transaction took place after 31 December 2025 and, as such, represents a non-adjusting post balance sheet event in accordance with FRS 102. The sale does not affect the financial position of the Company as at the reporting date.
Directors
The directors shown below have held office during the whole of the period from
1 January 2025
to
31 December 2025
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
| 2025 | 2024 | |
|---|---|---|
|
|
£ |
£ |
| Turnover: |
|
|
| Cost of sales: |
|
(
|
| Gross profit(or loss): |
|
|
| Administrative expenses: |
(
|
(
|
| Operating profit(or loss): |
( |
|
| Interest receivable and similar income: |
|
|
| Interest payable and similar charges: |
(
|
|
| Profit(or loss) before tax: |
( |
|
| Tax: |
|
(
|
| Profit(or loss) for the financial year: |
( |
( |
As at
| Notes | 2025 | 2024 | |
|---|---|---|---|
|
|
£ |
£ |
|
| Fixed assets | |||
| Tangible assets: | 3 |
|
|
| Investments: | 4 |
|
|
| Total fixed assets: |
|
|
|
| Current assets | |||
| Debtors: | 5 |
|
|
| Cash at bank and in hand: |
|
|
|
| Total current assets: |
|
|
|
| Creditors: amounts falling due within one year: | 6 |
(
|
(
|
| Net current assets (liabilities): |
|
|
|
| Total assets less current liabilities: |
|
|
|
| Total net assets (liabilities): |
|
|
|
| Capital and reserves | |||
| Called up share capital: |
|
|
|
| Profit and loss account: |
|
|
|
| Total Shareholders' funds: |
|
|
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 December 2025
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
Valuation information and policy
Other accounting policies
for the Period Ended 31 December 2025
| 2025 | 2024 | |
|---|---|---|
| Average number of employees during the period |
|
|
for the Period Ended 31 December 2025
| Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
|---|---|---|---|---|---|---|
| Cost | £ | £ | £ | £ | £ | £ |
| At 1 January 2025 |
|
|
|
|
|
|
| Additions | ||||||
| Disposals | ||||||
| Revaluations | ||||||
| Transfers | ||||||
| At 31 December 2025 |
|
|
|
|
|
|
| Depreciation | ||||||
| At 1 January 2025 |
|
|
|
|
|
|
| Charge for year |
|
|
|
|
||
| On disposals | ||||||
| Other adjustments | ||||||
| At 31 December 2025 |
|
|
|
|
|
|
| Net book value | ||||||
| At 31 December 2025 |
|
|
|
|
|
|
| At 31 December 2024 |
|
|
|
|
|
for the Period Ended 31 December 2025
Shares in group undertakings and participating interests 2025= £23,994 2024= £23,994 Details of the Company's subsidiary at 31 December 2025 is as follows: Name of undertaking: Insight PV & Consulting GmbH Registered office: Leipziger Platz 15 10117, Berlin Germany Principal activity: Pharmacovigilance & regulatory advisory services Class of shares held: Ordinary Holding %: 100
for the Period Ended 31 December 2025
| 2025 | 2024 | |
|---|---|---|
| £ | £ | |
| Trade debtors |
|
|
| Prepayments and accrued income |
|
|
| Other debtors |
|
|
| Total |
|
|
for the Period Ended 31 December 2025
| 2025 | 2024 | |
|---|---|---|
| £ | £ | |
| Trade creditors |
|
|
| Taxation and social security |
|
|
| Other creditors |
|
|
| Total |
|
|